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ABSTRACT
Purpose To improve the delivery of liposomes to tumors using
P-selectin glycoprotein ligand 1 (PSGL1) mediated binding to
selectin molecules, which are upregulated on tumorassociated
endothelium.
Methods PSGL1 was orientated and presented on the surface
of liposomes to achieve optimal selectin binding using a novel
streptavidin-protein G linker molecule. Loading of PSGL1 lip-
osomes with luciferin allowed their binding to e-selectin and
activated HUVEC to be quantified in vitro and their stability,
pharmacokinetics and tumor accumulation to be tested in vivo
using murine models.
Results PSGL1 liposomes showed 5-fold (p<0.05) greater
selectin binding than identically formulated control liposomes
modified with ligand that did not contain the selectin binding
domain. When added to HUVEC, PSGL1 liposomes showed
>7-fold (p<0.001) greater attachment than control liposomes.
In in vivo studies PSGL1 liposomes showed similar stability and
circulation to control liposomes but demonstrated a >3-fold
enhancement in the level of delivery to tumors (p<0.05).
Conclusions The technologies and strategies described here
may contribute to clinical improvements in the selectivity and
efficacy of liposomal drug delivery agents.
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tumor
ABBREVIATIONS
Fc immunoglobulin fragment crystallizable region
HRP horse radish peroxidise
HUVEC human umbilical cord venous endothelial cells
IV intravenous
PSGL1 P-selectin glycoprotein ligand 1
INTRODUCTION
Actively targeting drug loaded liposomes to surface recep-
tors up-regulated on tumor cells should improve anti-tumor
efficacy. However, despite the assistance provided by the
enhanced permeability retention effect (1) there are still
many limitations to achieving such targeting. The high
interstitial pressure and dense extracellular matrix within
tumors (2), makes penetration beyond the perivascular re-
gion inefficient (3–5), thereby lowering the opportunity for
interaction between targeted liposomes and target cells.
Furthermore the receptors available as targets often lack
the desired specificity or presentation on tumor cells and
show variable expression between different cancer types.
In response to these limitations, targeting therapeutics to
the endothelial cells which support tumors has emerged as
an attractive alternative strategy. In contrast to normal
endothelium, tumor-associated endothelial cells have an
inflamed phenotype due to activation by cytokines produced
by the tumor (6). This pro-inflammatory activation pro-
motes increased proliferation and results in up-regulated
levels of cell surface receptors such as αvβ3 integrins, vascu-
lar endothelial growth factor receptors, vascular cell adhe-
sion proteins and selectins (7–10). The properties and
surface receptor expression profiles of tumor-associated en-
dothelium are common amongst patients with the same type
of cancer (11) and amongst different types of cancer (12–14),
and yet still distinct from normal endothelium. Therefore,
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targeting these receptors should enable the development of
therapeutics which are active against a wide range of cancer
types whilst maintaining their selectivity for tumor-
associated rather than normal endothelium. It is also note-
worthy that intravenously delivered therapeutics have rapid
and direct contact with tumor-associated endothelium.
Targeting to selectins expressed on endothelial cells is a
particularly attractive strategy. Selectins are a family of
calcium dependent type-I transmembrane protein com-
prised of: platelet (P)-selectin (expressed on endothelial cells
as well as platelets), endothelium (E)-selectin and leukocyte
(L)-selectin. P and E-selectin play a crucial role in recruit-
ment of leukocytes to inflamed endothelium, a process
which takes place despite the presence of shear flow and
multiple other bloodstream components. This is possible
because selectin mediated binding triggers a mechanism of
‘rolling’ and slowing of leukocytes (15,16). Selectins may
therefore be ideal target receptors as their physiological role
so closely matches the requirements needed to achieve effi-
cient binding of blood borne therapeutic agents to the
tumor-associated endothelium. Indeed, success in achieving
selectin mediated endothelial targeting in pre-clinical mod-
els has been previously reported for viral and non-viral gene
delivery vectors (15,16). It is notable that in these reports
care was taken to ensure that correct ligand presentation
and orientation were achieved to permit optimal receptor
binding. The application of protein A or G has allowed
antibodies or ligands bearing the Fc domain of immuno-
globulin to be linked to therapeutics with high affinity whilst
preserving receptor binding regions (17,18). Similar strate-
gies have also been reported utilising the even higher affinity
interaction between bungarotoxin and its ligand (19).
Here we report the first in vivo use of P-selectin glycopro-
tein ligand 1 (PSGL1) to enhance the targeting of liposomes
to tumor endothelium. We demonstrate that by designing a
novel conjugation strategy which presents PSGL1 on the
surface of the liposome in the correct orientation specific
binding to endothelial cells in vitro and enhancements in
tumor accumulation in vivo can be achieved.
MATERIALS AND METHODS
Materials
Hydrogenated soy phosphatidylcholine (HSPC, 840058)
and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[biotinyl(polyethyleneglycol)-2000] (DSPE-PEG-Biotin,
880129) were purchased from Avanti Polar Lipids (USA).
Cholesterol (C8667), Streptavidin (S4762) and protein G
(19459) were purchased from Sigma (UK). Biotinylated-
horse radish peroxidise (43-2040) was purchased from Invi-
trogen (CA, USA). Goat IgG-horse radish peroxidise
(12348) was purchased from Millipore (UK). Fc linked
PSGL1 (3345-PS) and the control Fc lacking the PSGL1
domain (110-HG) were purchased from R and D Systems
(UK). Human Umbilical Vein Endothelial cells (HUVECs;
PromoCell, Germany) were maintained in EGMTM-2-
Endothelial Cell Medium-2 (Cambrex Bio Science, USA),
supplemented with hydrocortisone, h-FGF-B, VEGF, R3-
IGF-1, ascorbic acid, heparin, FBS, hEGF, and GA-1000
(Cambrex Bio Science, USA). E-selectin was purchased
from R and D systems. E1, E3-deleted Ad5 expressing
cytomegalovirus immediate-early (CMVIE) promoter-
driven luciferase (Adluc) was purchased from Hybrid Bio-
systems Ltd (UK). D-Luciferin and B16-F10-luc cells were
purchased from Caliper life sciences (USA) and maintained
as recommended by the manufacturer.
Formulation of Liposomes and Luciferin Loading
Liposomes were formulated by mixing HSPC, cholesterol
and DSPE-PEG or DSPE-PEG-biotin at ratios of 55:40:5 in
2 chloroform: 1 methanol, in a round bottomed flask. After
complete dissolution rotary evaporation for 30 min at 55°C
achieved a thin film which after drying under high vacuum
overnight was rehydrated in 300 mM Tris pH 10 for
60 min. Sizing was achieved by extrusion at 55°C using a
LiposoFast extruder (purchased from GC technology Ltd,
UK) with 11 passes through a 400 nm filter (86-039) fol-
lowed by a 11 passes through a 100 nm (86-037) filter.
Buffer exchange into 25 mM citrate, 150 mM NaCl buffer
pH 5 using a PD10 column (GE healthcare) created a trans-
bilayer pH gradient which was used to actively load luciferin
dissolved in 25 mM citrate, 150 mM NaCl buffer. After
incubation of 1.8 mL of 20 mg/mL liposomes with luciferin
(30 mg in 100 μL) overnight at room temperature, non-
loaded luciferin was removed and buffer exchanged for
phosphate buffered saline. Luciferin loading was calculated
by the addition of a 1:1 mix of buffer containing free
recombinant luciferase (25 mM HEPES, 2 mM EDTA,
60 μg/mL BSA, 40 μg/mL DTT, 20 μg/mL luciferase
(Sigma, F3776), pH 7.5) and an ATP buffer (25 mM
HEPES, 2 mM EDTA, 1 mM ATP, pH 7.5). Measurements
were taken in a luminometer (Berthold, LB9507) following
heating sample to 100°C for 5 min or not and compared to
a standard curve of identically treated dilutions of free
luciferin. The percentage of encapsulated luciferin was cal-
culated by the formula ((μg post heating – μg pre-heating) /
μg post heating) × 100. After purification and buffer ex-
change into PBS using a PD column the percentage of
encapsulated luciferin was found to be in excess of 97%.
Dynamic light scattering was performed using a Malvern
Zetasizer 3000 (Malvern Instruments), with 3 sub-runs of 10
and automatic analysis, on 3 separate samples.
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Formulation and Testing of a Protein G-Streptavidin
Linker and Addition to Liposomes
Streptavidin was modified with protein G at a range of
ratios using EDC chemistry as modified from (20). Strepta-
vidin 0.1 mg was dissolved in 100 μL (final conc 0.013 mM)
of 0.1 M MES (2-[morpholino]ethanesulfonic acid), 0.1 M
NaCl, buffer pH 5.6 and 10 μL 0.04 mg (2.5 mM final
conc), of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
hydrocholoride (EDC, Pierce) and Sulfo-NHS (1 mg,
5 mM final conc) was then added and after 15 min at room
temperature buffer pH was raised using PBS. Protein G was
then added at a range of ratios for 2 h at room temperature,
as defined in figure legends. Analysis of changes to protein
size and ligand binding ability was performed using
SDSPAGE with Coomassie staining or transfer onto nitro-
cellulose and blotting with biotinylated-horse radish perox-
idise (HRP) (Invitrogen) or Fc-HRP (Millipore) in 5% milk/
PBS for 1 h, followed by 3 × 10 min washes in PBS/Tween
0.01%. Nitrocellulose was developed with ECL reagent (GE
Healthcare) and images captured and densiometrically ana-
lysed using an Alpha Innotech imager and FluorChemHD2
software. The ratio which gave optimal maintenance of
binding to both Fc and biotin was identified (1 streptavidin
: 2 protein G) and used for addition to luciferin loaded
liposomes incorporating PEG-biotin (see Formulation of
Liposomes and Luciferin Loading). After incubation over-
night excess protein G-streptavidin was removed by separa-
tion on a PD10 column (GE healthcare).
In Vitro Assays of Binding to Selectins
Maxisorb ELISA plates (Nunc) were coated with E-selectin
(R and D systems) as described by (21). Optimisation and
confirmation of coating was provided using a BCA assay
(Sigma). E-selectin (50 μg/mL), dissolved in PBS was added
50 μL/well overnight at 4°C, then removed before blocking
with 100 μL PBS/1% bovine serum albumin for 1 h at
room temperature. After three washes in 200 μL of PBS,
50 μL of luciferin loaded Fc-control or PSGL1 liposomes in
PBS was added per well for 30 min at room temperature.
Sample was then removed and 10 washes in 200 μL of PBS
performed. 200 μL of PBS was placed in each well and the
plate heated to 70°C degrees. Sample was transferred into
luminometer tubes, luciferase/ATP was added as in Formu-
lation of Liposomes section and measurement performed
using a luminometer (Berthold, LB9507). For assaying bind-
ing to HUVEC, cells were plated at 10,000 per well in a
black 96 well plate. To achieve luciferase expression in the
HUVECs so that the binding of luciferin loaded liposome
could be assayed the cells were infected with an adenovirus
vector expressing the luciferase transgene (Adluc). After
24 h, 500 of particles of Adluc were added per cell for
90 min before washing and returning to the incubator
overnight. Liposomes (2 μL per well) were then added in
100 μL fresh media. The luciferase/luciferin signal was then
assayed at 5, 10, 20 and 60 min using a Wallac 1420 plate
reader. 5 × washes in 100 μL PBS were then performed and
media was replaced and incubation and measurement con-
tinued for the next 27 h. Experiments were performed with
n04, results were typical of three separate experiments and
analysis of significance was obtained using ANOVA com-
parisons and PRISM software.
In Vivo Analysis of Release, Circulation, and Tumor
Accumulation
B16-F10-luciferase cells were grown and implanted (5×105
cells) into the flank of C57 Bl6 mice. After 3 weeks when
tumors had reached a size of between 500 and 700 mm3
their luciferase expression was confirmed and compared by
injecting 100 μL of 15.8 mg/mL of free luciferin in PBS
intravenously and imaging after 5 min using an IVIS 100
(Caliper Life Sciences, USA). 2 days later mice were re-
imaged to verify their return to background luminescence
levels and then 80 μL liposomes / 280 μg of luciferin sample
was injected intravenously. IVIS images and blood samples
(20 μL) were taken at 15, 30, 60 and 120 min after injection
after which time mice were culled and organs harvested for
quantification of biodistribution and tumor accumulation.
Samples were lysed and heated and luciferin content calcu-
lated against standard curves made with identically pro-
cessed organs from untreated mice which had been spiked
with serial dilutions of known amounts of luciferin loaded
liposomes. Heating was demonstrated to both release still
encapsulated luciferin and destroy endogenous tumor lucif-
erase. Organ and blood associated luciferin could therefore
be calculated by the addition of luciferase/ATP as in For-
mulation of Liposomes section. Data shown were typical of
two experiments. Analysis was performed by ANOVA using
PRISM.
RESULTS
Protein G-Streptavidin Conjugates with Ligand
Binding Properties of Both Sub-Units
The commercial availability of DSPE-PEG-biotin makes
the streptavidin-biotin interaction an attractive and viable
proposition when considering methods of achieving attach-
ment of retargeting ligands to liposomes. Similarly the com-
mercial availability of a P-selectin glycoprotein ligand-1
(PSGL1) fusion protein bearing human IgG Fc regions
provides the possibility of linking this retargeting agent via
its interaction with protein A or G, as reported for non-viral
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and viral gene delivery agents (17,22). However mechanisms
of linking streptavidin binding to protein G binding are not
presently available and so we developed the strategy out-
lined (Fig. 1a), and in so doing created a novel biomaterial
with this dual binding functionality. The use of EDC/
SufoNHS chemistry allowed the rapid and reproducible
production and testing of functional conjugates (Fig. 1b–d).
The complete absence of a band of unmodified protein G
(at approximately 30 kDa) in lane 1 of Fig. 1b suggests that
at this ratio (3 streptavidin : 1 protein G) 100% of the
protein G has been bound to streptavidin. Whilst the faint
band at 30 kDa present in lane 2 indicates that at a ratio of 1
streptavidin : 4 protein G, not all the protein G was conju-
gated. Indeed, further analysis (Fig. S1a) showed that at this
ratio 24% of the protein G remained unmodified. The
presence of high molecular weight bands in Fig. 1b, lanes
1 and 2 (>160 kDa) confirmed the formation of protein G-
streptavidin conjugates. In control lanes 3 and 4, which
contained sample with no streptavidin, the protein G mi-
grated to its predicted weight. Blotting onto nitrocellulose
enabled the capacity of the conjugates to bind to biotin
(Fig. 1c) or Fc domains (Fig. 1d) to be assayed. At a ratio
of 3 streptavidin to 1 protein G (lane 1) intense binding was
evident at several molecular weights between 80 and
200 kDa (Fig. 1c). A band of unmodified streptavidin was
also detected at about 70 kDa. The lower intensity of these
bands in lane 2 indicated that the increased level of protein
G in these conjugates had diminished the ability of the
streptavidin to bind to biotin. Notably no staining was
evident in lanes 3 demonstrating no cross-reactivity of pro-
tein G with biotin-HRP (Fig. 1c). The conjugates in lane 1
showed decreased binding compared to those in lane 2
when probed with Fc-HRP (Fig. 1d). As a result of these
studies the ratio of 1 streptavidin : 2 protein G was identified
as the optimal to maintain high binding capacity to both
biotin and Fc (Fig. S1b). Although this ratio still resulted in a
small level (6%) of protein G remaining unmodified, this
was removed by size exclusion chromatography before ad-
dition of PSGL1 to liposomes-streptavidin-protein G. These
data confirmed the creation of a novel biomaterial which
could be used in combination with biotinylated liposomes to
create a platform vector for the testing of any targeting
strategy using any Fc bearing molecule (e.g. antibodies,
fusion proteins).
PSGL1 Modification of Liposomes for Selectin
and HUVEC Binding
Dynamic light scattering was used to assess the influence of
ligand addition on the stability, size and monodispersity of
liposomes. Throughout the stages of modification with pro-
tein G-streptavidin, purification, and then addition of
PSGL1 or ‘Fc-control’ protein, liposomes maintained a
polydispersity below 0.1 and a size of approximately
150 nm (Fig. 2a). This size is desirable for intravenously
delivered agents as it is above the cut-off of the hepatic
endothelial fenestrae in pre-clinical models and patients
(23,24). This should provide liposomes with reduced hepatic
clearance, extended circulation and therefore enhanced in-
teraction with tumor associated endothelium. Repeat DLS
analysis of liposomes after one month storage showed main-
tenance of these size and polydispersity values, demonstrat-
ing that surface modification with PSGL1 or control ligand
had not detrimentally influenced stability.
The interaction between the enzyme luciferase and its
substrate luciferin produces dose dependent quantifiable
photon emissions. Loading of liposomes with luciferin there-
fore enabled their binding to selectin coated plates to be
assayed with great sensitivity (see Materials and Methods).
Following a 1 h incubation with liposomes and thorough
washing with PBS, binding was quantified by heating the
plate to release luciferin which was then added to recombi-
nant luciferase enzyme and assayed by luminometry.
PSGL1 liposomes showed 5-fold (p<0.05) greater binding
to the selectin coated plates than control Fc-liposomes
(Fig. 2b). This binding could be inhibited by pre-
incubation of the plate with a 100-fold excess of free
PSGL1.
The specific PSGL1 mediated targeting of liposomes was
confirmed in studies using HUVEC expressing luciferase
(Fig. 2c). After a period of 60 min to allow interaction
between cells and liposomes, cells were thoroughly washed
to remove any non-bound liposomes. During the subse-
quent 60 min no difference in luciferin luminescence, was
observed for cells exposed to PSGL1 liposomes compared to
those exposed to Fc control liposomes or non-modified lip-
osomes, perhaps indicative of the need for a period to allow
release of luciferin from PSGL1 liposomes bound to cells.
However, from 3 h onwards cells exposed to PSGL1 lip-
osomes started to produce significantly increased lumines-
cence signal compared to controls, indicative of improved
binding. This differential increased over time reaching 7-
fold by 27 h (p<0.001). In previous reports of in vitro selectin
mediated targeting, binding required activation of the en-
dothelial cells with tumour necrosis factorα (TNFα) (25).
Notably the targeting observed in our studies was achieved
without the addition of TNFα. This suggests that, in accor-
dance with previous reports (26), the use of Adluc to achieve
luciferase expression in these cells was a sufficient stimulus to
also induce selectin presentation. In studies where delivery
was compared with and without a 4 h pre-incubation with
100 ng/mL of TNFα, similar results to those in Fig. 2c were
obtained (Fig. S2b). Exposure of HUVEC to Adluc or
TNFα and probing with Fc-control or PSGL1 confirmed
the presence and ligand binding functionality of selectins
under these conditions (Fig. S2c).
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In Vivo Testing of PSGL1 Liposomes
In addition to enabling simple, accurate and sensitive mea-
surement of activity in vitro as described above, loading of
liposomes with luciferin also enabled in vivo activity to be
characterised. C57BL6 mice bearing B16-F10-luciferase
tumors were a good model for these studies as they allowed
pre-testing and validation with non-encapsulated free lucif-
erin to ensure that no significant inter or intra-group differ-
ences in tumor size or vascular supply existed (Fig. S3a and
S3b). After 48 h to allow the free luciferin to clear, these
mice were then dosed intravenously with unmodified lip-
osomes, Fc control liposomes or PSGL1 liposomes. For 2 h
post injection images were taken and analysed using an IVIS
system to characterise liposome stability and blood samples
were taken to provide pharmacokinetic data. It is clear that
within the 2 h time-frame of the experiment no significant
inter or intra-group differences in the signal from the B16-
F10-luciferase tumors were evident (Fig. 3 a and b). This
demonstrates that over this duration the luciferin within the
non-modified liposomes, Fc-control liposomes and PSGL1
liposomes remained similarly encapsulated, indicating that
all the formulations possessed similar stability in the blood-
stream. In accordance with these findings, in studies using
liposomes with a similar composition to the non-modified
liposomes used here, Kheirolomoom et al. calculated a lu-
ciferin release rate which approached zero after 30 min (27).
The 2 h time-frame of the experiments described here was
chosen to allow specific PSGL1 mediated binding to tumor
associated endothelia to be distinguished from EPR medi-
ated passive accumulation in the tumor, the effects of which
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Fig. 1 Production of a protein
G-streptavidin conjugate for link-
age of immunoglobulin G Fc
containing ligands to liposomes.
(a) Outline of the strategy for the
linkage of liposomes presenting
PEG-biotin to the targeting ligand
PSGL1-Fc via a linker comprised
of streptavidin (for biotin binding)
and protein G (for Fc binding). (b)
Coomassie stained SDSPAGE of
protein G-streptavidin conjugates
formed at ratios of; lane 1 0 3
streptavidin : 1 protein G, lane 2
0 1 streptavidin : 4 protein G,
lane 3 0 free protein G in reac-
tion buffers, lane 4 0 free protein
G direct from stock. (c) Probing
of nitrocellulose with biotin-HRP;
lane 1 0 3 streptavidin : 1 protein
G, lane 2 0 1 streptavidin : 4
protein G, lane 3 0 free protein G
in reaction buffers. (d) Probing of
nitrocellulose with Fc-HRP;
lane 1 0 3 streptavidin : 1 protein
G, lane 2 0 1 streptavidin : 4
protein G, lane 3 0 free protein G
in reaction buffers.
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studies revealed that non-modified liposomes and PSGL1
liposomes showed almost identical blood clearance profiles
with bloodstream concentrations which were halved
10 minutes after injection and then stabilised to 20% of
the injected dose over the next 110 min (Fig. 4a). This
profile suggests a saturable first pass hepatic clearance
mechanism, perhaps mediated by kupffer cell capture. No-
tably the clearance of Fc-control liposomes followed the
same profile but a concentration of just 10% of the injected
dose was recovered from the bloodstream at 2 h. In studies
using liposomes with a similar composition to the non-
modified liposomes used here, Kheirolomoom et al. reported
the same biphasic clearance profile (27). Analysis of liver,
spleen and lung accumulation supported a role for first pass
hepatic clearance with over 30% of the injected dose being
recovered from the liver in all treated mice (Fig. 4b). Liver
accumulation occurred despite the inclusion of polyethylene
glycol (PEG) in the liposomes tested here. Whilst such
PEGylation did provide much reduced liver capture com-
pared to non-PEGylated liposomes (data not shown), reduc-
ing this capture further by increasing the percentage of
PEGylation used may allow further enhancements in circu-
lation and tumor accumulation.
Post-cull analysis of tumor accumulation demonstrated
that approximately 1.2% of the injected dose of PSGL1
liposomes had accumulated per gram of tumor (1.2% ID/
g), during the 2 h following intravenous administration. This
proved to be a significant (p<0.05) and substantial (5-fold or
3.5-fold) increase compared non-modified liposomes or Fc-
control liposomes (Fig. 4c). As all these liposome formula-
tions demonstrated identical bloodstream stability and sim-
ilar clearance profiles this increase is indicative of PSGL1
ligand providing increased association with tumor-
associated endothelium. Probing of tumor cryosections with
PSGL1 confirmed the presence of selectins on this endothe-
lium (Fig. S3c). The level of tumor association of non-
modified liposomes is in accordance with the levels reported
in pre-clinical studies which have utilised radiolabelling to
demonstrate that Doxil like formulations achieve 0.6% ID/
g tumor after 18 h (29) or 0.2% ID/g tumor after 4 h (30).
Recently a strategy for targeting liposomes directly to
tumors achieved an impressive 4.7% ID/g of tumor after
48 h (31), an improvement over the level observed in our
studies. This improvement may be due to the longer dura-
tion allowed before assaying and the enhanced ability to
achieve efficient internalisation. The different characteristics
of the target tumor models used may also be an important
factor, as recently demonstrated by Ogawara et al. (32). The
protein G-streptavidin ‘platform’ vector and in vivo test sys-
tem we have developed could allow a vast range of Fc
containing antibodies or fusion proteins to be directly com-
pared, so that optimal targeting strategies, conditions and
ligands could be identified. Although the high immunoge-
nicity of streptavidin may limit its ultimate clinical applica-
tion the optimal targeting ligands identified by these studies














































































Fig. 2 The influence of PSGL1 addition on the physicochemical and
biological activity of liposomes. (a) Dynamic light scattering analysis of the
size and polydispersity of liposomes or modified liposomes. (b) Ability of
Fc-control or PSGL1 liposomes to adhere to E-selectin coated plates, as
measured by detection of luminescence in wells after incubation with
luciferin loaded liposomes, washing, rupture of liposomes and luciferase
enzyme addition. N03, SD shown, significance (p<0.05) calculated by
ANOVA. (c) Ability of liposomes to adhere to / deliver luciferin to HUVECs
expressing the luciferase enzyme, as assayed after incubation with luciferin
loaded liposomes, washing, and multiple subsequent luminescence meas-
urements. Black line and diamonds 0 unmodified liposomes, blue line and
squares 0 Fc control liposomes, red line and triangles 0 PSGL1 liposomes.
N04, standard error (se) shown, significance (p<0.001) calculated by
ANOVA with Tukey post test all samples comparison using PRISM.
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DISCUSSION
The advantages of targeting drug delivery to tumor-associated
vasculature has long been recognised (33). Selectin molecules
provide a particularly attractive target due to their upregula-
tion on inflamed endothelium and the fact that their physio-
logical role in leukocyte recruitment mimics that required to
bind and slow drug delivery macromolecules under conditions
of shear flow. As a result, several investigations using a variety
of selectin ligands to target liposomes have been reported (34)
(25) (35), with impressive in vitro results. Here we present the
first demonstration that such targeting can improve tumor
accumulation in in vivo studies performed using pre-clinical
tumor bearing models. The reported difficulties of synthesis-
ing and using sialyl Lewis(X) (36) and our previous experience
comparing anti-selectin antibodies to the PSGL1 ligand for
retargeting of adenovirus vectors (17) persuaded us that the
PSGL1 ligand would provide optimal ease of use, efficiency of
targeting and reduced immunogenicity. Previous studies have
also demonstrated the advantage of attaching targeting ligand
to therapeutic agent in ways that use epitopes of the ligand
that are not involved in receptor binding and achieve
appropriate orientation of the ligand (37) (19). To meet this
requirement we developed a new protein G-streptavidin bio-
material as a linker between biotin on the liposome surface
and Fc regions in the PSGL1. This conjugate was produced
by chemically cross-linking the two recombinant proteins. We
believe the chemical conjugation strategy we employed to be
the most efficient and assured method considered the chal-
lenges faced in trying to engineer and express recombinant
streptavidin fusion proteins. Although the problems of inclu-
sion body formation and inappropriate refolding of native
streptavidin produced in E. coli have been overcome (38,39),
in the case of fusion proteins the yield of correctly folded
protein is often sub-optimal and a general refolding method
has not been established. A sophisticated enzyme mediated
approach to circumvent this problem and produce a GFP-
streptavidin fusion protein has recently been published, but
this has not yet been attempted for a protein G-streptavidin
(40). Our optimised protein G-streptavidin linker demonstrat-
ed binding to both Fc domains and biotin (Fig. 1) and pro-
duced a ‘platform’ system that could be used to test the ability
of any Fc bearing antibody or fusion protein to target lip-
osomes. In our in vitro experiments substantial and significant
a
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Fig. 3 Stability of liposomes
following intravenous delivery to
mice bearing B16-F10-luciferase
tumors. (a) An IVIS system was
used to capture luminescence
from luciferase tumors at 15, 30,
60 and 120 min post injection of
80 μL/280 μg of luciferin loaded
liposomes. (b) Luminescence sig-
nal from tumors was quantified
and plotted against time for the 3
liposome formulations. Black line
and diamonds 0 unmodified lip-
osomes (n03), blue line and
squares 0 Fc control liposomes
(n05), red line and triangles 0
PSG1 liposomes (n04), se
shown, no significant differences
were evident as calculated by
ANOVA.
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increases in the attachment of liposomes to E-selectin and
activated HUVEC was achieved using PSGL1 (Fig. 2). To
date, there have been no reports testing the ability of selectin
targeted liposomes to accumulate in tumor-associated
endothelium in vivo, perhaps because such experiments fell
outside the scope of previous studies. In our studies loading
liposomes with luciferin allowed in vivo stability, pharmacoki-
netics and tumor accumulation to be sensitively and accurate-
ly measured (Fig 3 and 4). Liposomes targeted with PSGL1
showed similar stability and pharmacokinetics to non-targeted
controls but demonstrated significantly and substantially in-
creased accumulation in tumors. Levels obtained after just 2 h
approached 1.2% of the injected dose per gram of tumor.
PEGylated liposomes demonstrate good circulation and EPR
assisted tumor accumulation, however their enhanced stability
means that they achieve sub-optimal release of therapeutic
cargo and poor penetration beyond the perivascular space (3).
The application of ultrasound offers a method by which the
targeted release of drug payload from such liposomes can be
non-invasively triggered (41). This is an especially attractive
strategy when combined with the delivery of microbubbles,
which allows powerful ‘cavitation’ events to be generated at
diagnostic ultrasound pressure (42). However, following co-
delivery of liposomes and microbubbles the EPR effect will
allow entry of liposomes (100–200 nm) into tumors whilst
excluding microbubbles (~2.5 μm), and such partitioning will
prevent the microbubbles impacting on the liposomes. By
increasing accumulation of liposomes on the tumor-
associated endothelium using PSGL1 targeting, it is hoped
we can enhance the efficiency of microbubble/ultrasound-
induced tumor-specific release of drug from liposomes. Our
further studies will investigate the combination of these strat-
egies for enhanced tumor therapy.
CONCLUSION
Here we describe the novel application of PSGL1 to lip-
osomes to provide successful targeting to selectins. This was
achieved by the chemical formulation of a novel biomateri-
al, a protein G-streptavidin conjugate, which retained the
ligand binding activities of both its sub-units and could
therefore act as a linker between liposomes and the PSGL1
molecule. The creation of this linker provides the opportu-
nity to test a range of different ligands containing the im-
munoglobulin Fc region (antibodies, fusion proteins), using
the same ‘platform’ protein G-streptavidin modified lipo-
some formulation. This strategy has the advantage of linking
ligands to liposomes via domains that are not involved in
their interaction with cell surface receptors. Such optimal
orientation and presentation proved beneficial in our studies
using PSGL1 which provided substantial enhancements in
selectin binding in vitro. The subsequent significant increases
in tumor accumulation we observed using PSGL1 targeted
liposomes in a pre-clinical xenograft model, suggests such a
strategy may provide clinical improvements in the selectivity








































































Fig. 4 Pharmacokinetics and organ and tumor accumulation of liposomes
following intravenous delivery to mice bearing B16-F10-luciferase tumors.
(a) Blood samples collected at 5, 10, 30, 60, 90 and 120 minutes were
analysed for luciferin content by heating followed by luciferase enzyme
addition and luminometry. Black line and diamonds 0 unmodified lipo-
somes (n03), blue line and squares 0 Fc control liposomes (n05), red line
and triangles 0 PSG1 liposomes (n04), se shown, no significant differences
at 120 min were evident as calculated by ANOVA. (b) Liposome accumu-
lation in specified organs was quantified at 120 min post injection by
homogenising organs heating, adding luciferase enzyme and measuring
by luminometry. Unmodified liposomes n03, Fc control and PSGL1 lip-
osomes n05, data calculated as % of injected dose / whole organ. (c)
Liposome accumulation in tumors was quantified at 120 min post injection
by homogenising tumors, heating, adding luciferase enzyme and measuring
by luminometry. Unmodified liposomes n03, Fc control and PSGL1 lip-
osomes n05, data calculated as % of injected dose / gram of tumor (%ID/
g), significant difference (p<0.05) evident as calculated by ANOVA with
Tukey post test all samples comparison using PRISM.
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